Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

about

Neutrophils, a candidate biomarker and target for radiation therapy?

P2860

Q51802063-4EF6C18A-0200-4020-BCE1-2B68B8A30B03

P2860

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

Item

http://www.wikidata.org/entity/Q41347312

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

@en

type

Item

label

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

@en

prefLabel

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

@en

P1476

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat

@en

P2093

Christophe Hennequin

http://www.w3.org/2001/XMLSchema#string

Céline Leteur

http://www.w3.org/2001/XMLSchema#string

Frédéric Law

http://www.w3.org/2001/XMLSchema#string

Frédérique Mégnin

http://www.w3.org/2001/XMLSchema#string

Ioana Kloos

http://www.w3.org/2001/XMLSchema#string

Isabelle Martins

http://www.w3.org/2001/XMLSchema#string

Nazanine Modjtahedi

http://www.w3.org/2001/XMLSchema#string

Sofia Rivera

http://www.w3.org/2001/XMLSchema#string

Stéphane Depil

http://www.w3.org/2001/XMLSchema#string

P2860

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

DNA double-strand breaks: signaling, repair and the cancer connection

Histone acetyltransferases

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Anticancer activities of histone deacetylase inhibitors

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Un

P304

56210-56227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.14813

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric Deutsch

Jean-Luc Perfettini

P577

2017-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28915585

http://www.w3.org/2001/XMLSchema#string

P932

5593556

http://www.w3.org/2001/XMLSchema#string

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

about

P2860

P2860

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932